Phases précoces tumeurs solides M15-819 A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy in Subjects With Advanced Solid Tumors. Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ SAFIR-TOR Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women. Paris, Saint-Cloud PAUL-HENRI COTTU
Phases précoces tumeurs solides INDUCE-1 (GSK-204691) A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides MK4621-002 A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Solid Tumors Paris
Phases précoces tumeurs solides M16-074 A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors. Paris
Phases précoces tumeurs solides ARROW (BLU-667-1101) A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Paris NICOLAS GIRARD
Phases précoces tumeurs solides MK-1454-001 (STING) Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001) Paris EMANUELA ROMANO
Phases précoces tumeurs solides MOVIE M17 (GEP-15) A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour Paris CHRISTOPHE LE TOURNEAU
Phases précoces tumeurs solides CC-95775-ST-001 A PHASE 1B DOSE ESCALATION, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC OF CC-95775 IN SUBJECTS WITH ADVANCED SOLID TUMORS AND RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ HerSeq (PUMA-NER-9501) HER-Seq: A Blood-based Screening Study to Identify Patients with HER2 Mutations for;Enrollment into Clinical Research Studies of Neratinib Paris, Saint-Cloud